Has targeted therapy for melanoma made chemotherapy obsolete?

The Lancet Oncology

Volumn 14, Issue 8, 2013, Pages 676-677

  Gibney, Geoffrey T ^a,b   Sondak, Vernon K ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; DACARBAZINE; MITOGEN ACTIVATED PROTEIN KINASE; SELUMETINIB; TEMOZOLOMIDE; TRAMETINIB;

ADVANCED CANCER; BLEEDING; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EDEMA; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HUMAN; INFECTION; LETTER; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UPREGULATION; UVEA MELANOMA; VISUAL DISORDER;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; FEMALE; HUMANS; MALE; MELANOMA; MUTATION; NEOPLASMS, UNKNOWN PRIMARY; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 84879700284     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70298-5     Document Type: Letter

References (10)

1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
2. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
3. Ascierto PA, Schadendorf DA, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013, 14:249-256.
4. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367:107-114.
5. Robert C, Dummer R, Gutzmer R, et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol 2013, 14:733-740.
6. Catalanotti F, Solit DB, Pulitzer MP, et al. Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res 2013, 19:2257-2264.
7. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703.
8. Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013, 31:482-489.
9. Dahlman KB, Xia J, Hutchinson K, et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2012, 2:791-797.
10. Carvajal RD, Sosman JA, Quevedo F, et al. Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11(Gq/11) mutant (mut) uveal melanoma (UM). Proc Am Soc Clin Oncol 2013, 31. abstr 9003.